Related references
Note: Only part of the references are listed.Breaking a Vicious Cycle
Daniel F. Hayes et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Quantitative In Situ Measurement of Estrogen Receptor mRNA Predicts Response to Tamoxifen
Jennifer M. Bordeaux et al.
PLOS ONE (2012)
C-MYC Alterations and Association With Patient Outcome in Early-Stage HER2-Positive Breast Cancer From the North Central Cancer Treatment Group N9831 Adjuvant Trastuzumab Trial
Edith A. Perez et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Sample degradation leads to false-positive copy number variation calls in multiplex real-time polymerase chain reaction assays
Holly N. Cukier et al.
ANALYTICAL BIOCHEMISTRY (2009)
Use of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers
Richard M. Simon et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer
Maggie C. U. Cheang et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
A Decade of Tissue Microarrays: Progress in the Discovery and Validation of Cancer Biomarkers
Robert L. Camp et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Antigenicity testing by immunohistochemistry after tissue oxidation
C. Blind et al.
JOURNAL OF CLINICAL PATHOLOGY (2008)
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
EH Romond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Long-term preservation of antigenicity on tissue microarrays
KA DiVito et al.
LABORATORY INVESTIGATION (2004)
Automated subcellular localization and quantification of protein expression in tissue microarrays
RL Camp et al.
NATURE MEDICINE (2002)
Validation of tissue microarray technology in breast carcinoma
RL Camp et al.
LABORATORY INVESTIGATION (2000)
Paraffin section storage and immunohistochemistry - Effects of time, temperature, fixation, and retrieval protocol with emphasis on p53 protein and MIB1 antigen
K Wester et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2000)